Resistance manifestations of niraparib

Niraparib (Niraparib) is a drug used to treat ovarian cancer and is a PARP (polymerase-adenylate converting enzyme) inhibitor. Niraparib blocks the DNA repair process by inhibiting the activity of PARP enzyme, thereby preventing cancer cells from repairing damaged DNA, ultimately leading to cancer cell death. As first-line maintenance therapy in patients with advanced ovarian cancer, niraparib had manageable tolerability, consistent with that established in other indications.

Niraparib may be resistant to niraparib in the treatment of ovarian cancer. Generally refers to the situation where the response of cancer cells to drugs is weakened or completely ineffective, which may be caused by a variety of factors, including genetic mutations, enhancement of cell repair mechanisms, and changes in the tumor microenvironment. The mechanism of resistance to niraparib is not completely clear, but some studies have shown that it may be related to BRCA1/2 gene mutations. BRCA1/2 genes are key genes involved in DNA repair, and their mutations can lead to disorders of the DNA repair mechanism. Some studies have found that subclones with BRCA1/2 gene mutations appeared in cancer cells in some patients after receiving niraparib treatment, which may be one of the reasons for drug resistance.

NiraparibThe original drug has been launched in China and is included in medical insurance, but reimbursement is limited to eligible patients. The price of a common specification100mg*30 capsules per box may be more than 5,000 yuan. The original niraparib drug marketed overseas is more expensive than domestically. There are also generic niraparib drugs produced in other countries. Their pharmaceutical ingredients are basically the same as those of the original niraparib drug sold domestically and abroad. The price of 100mg*30 tablets per box produced by a Bangladesh pharmaceutical factory may be more than 1,000 yuan (the price may fluctuate due to exchange rates).